Deprescribing in Older Adults With Cardiovascular Disease.

Title
Publication TypeJournal Article
Year of Publication2019
AuthorsKrishnaswami A, Steinman MA, Goyal P, Zullo AR, Anderson TS, Birtcher KK, Goodlin SJ, Maurer MS, Alexander KP, Rich MW, Tjia J
Corporate AuthorsGeriatric Cardiology Section Leadership Council, American College of Cardiology
JournalJ Am Coll Cardiol
Volume73
Issue20
Pagination2584-2595
Date Published2019 05 28
ISSN1558-3597
KeywordsAged, Cardiovascular Diseases, Comorbidity, Deprescriptions, Drug-Related Side Effects and Adverse Reactions, Global Health, Humans, Inappropriate Prescribing, Incidence
Abstract

Deprescribing, an integral component of a continuum of good prescribing practices, is the process of medication withdrawal or dose reduction to correct or prevent medication-related complications, improve outcomes, and reduce costs. Deprescribing is particularly applicable to the commonly encountered multimorbid older adult with cardiovascular disease and concomitant geriatric conditions such as polypharmacy, frailty, and cognitive dysfunction-a combination rarely addressed in current clinical practice guidelines. Triggers to deprescribe include present or expected adverse drug reactions, unnecessary polypharmacy, and the need to align medications with goals of care when life expectancy is reduced. Using a framework to deprescribe, this review addresses the rationale, evidence, and strategies for deprescribing cardiovascular and some noncardiovascular medications.

DOI10.1016/j.jacc.2019.03.467
Alternate JournalJ. Am. Coll. Cardiol.
PubMed ID31118153
PubMed Central IDPMC6724706
Grant ListL30 AG060493 / AG / NIA NIH HHS / United States
R03 AG056446 / AG / NIA NIH HHS / United States
L30 AG060521 / AG / NIA NIH HHS / United States
K24 AG036778 / AG / NIA NIH HHS / United States
K24 AG049057 / AG / NIA NIH HHS / United States
U13 AG047008 / AG / NIA NIH HHS / United States